For the first time in Odisha, the hospital’s department of Clinical Hematology had successfully conducted a Haploidentical ...

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

Using the COMPASS model, researchers project risk of cardiac late effects for survivors of pediatric ALL at age 50 years.

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

An international clinical trial co-led by Roswell Park Comprehensive Cancer Center has demonstrated that the investigational ...

Nancy Delia knows cancer treatment saved her life after she was diagnosed with acute lymphoblastic leukemia (Ph+). But while ...

Chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) CLL and SLL are closely related diseases. In fact, many doctors consider them different versions of the same disease. The same type ...